{ }
001122334455554433221100
001122334455554433221100

new crispr treatment for sickle cell disease faces slow rollout challenges

Deshawn “DJ” Chow, a 19-year-old with sickle cell disease, received Casgevy, the first approved CRISPR-based treatment, after a year of waiting. Despite its promise, the rollout has been slow due to manufacturing complexities and insurance hurdles, with only a few patients treated since its December 2023 approval. Chow hopes the therapy will alleviate his pain and allow him to pursue activities like snowboarding, reflecting a cautious optimism for the future of sickle cell treatments.
Trending
Subcategory
Countries:
Companies:
Currencies:
People:

Machinary offers a groundbreaking, modular, and customizable solution that provides advanced financial news and statistical analysis. Our platform goes beyond traditional quantitative analysis, offering users a comprehensive understanding of real-time market dynamics, event detection, and risk analysis.

Address

Newsletter

© 2025 by Machinary.com - Version: 1.0.0.0. All rights reserved

Layout

Color mode

Theme mode

Layout settings

Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.